118 related articles for article (PubMed ID: 7923133)
21. A target-specific chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain.
Liao CW; Hseu TH; Hwang J
Appl Microbiol Biotechnol; 1995 Jul; 43(3):498-507. PubMed ID: 7632400
[TBL] [Abstract][Full Text] [Related]
22. TGF alpha-PE40 inhibits non-small cell lung cancer growth.
Draoui M; Siegall CB; FitzGerald D; Pastan I; Moody TW
Life Sci; 1994; 54(7):445-53. PubMed ID: 8309347
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
Siegall CB; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1991 Jun; 51(11):2831-6. PubMed ID: 1851660
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin.
Siegall CB; Xu YH; Chaudhary VK; Adhya S; Fitzgerald D; Pastan I
FASEB J; 1989 Dec; 3(14):2647-52. PubMed ID: 2556314
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944
[TBL] [Abstract][Full Text] [Related]
26. Increased cytotoxicity of interleukin 2-pseudomonas exotoxin (IL2-PE) chimeric proteins containing a targeting signal for lysosomal membranes.
Fishman A; Bar-Kana Y; Steinberger I; Lorberboum-Galski H
Biochemistry; 1994 May; 33(20):6235-43. PubMed ID: 8193138
[TBL] [Abstract][Full Text] [Related]
27. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
29. Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor alpha.
Reddy CC; Wells A; Lauffenburger DA
J Cell Physiol; 1996 Mar; 166(3):512-22. PubMed ID: 8600155
[TBL] [Abstract][Full Text] [Related]
30. Ligand binding characterization and molecular analysis of distinct epidermal growth factor-urogastrone receptors in cultured smooth muscle and epithelial cells from guinea pig intestine.
Yang SG; Ahmad S; Wong NC; Hollenberg MD
Mol Pharmacol; 1994 Aug; 46(2):256-65. PubMed ID: 8078489
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.
Kameyama S; Kawamata H; Pastan I; Oyasu R
J Cancer Res Clin Oncol; 1994; 120(9):507-12. PubMed ID: 8045915
[TBL] [Abstract][Full Text] [Related]
32. The role of transforming growth factor alpha in determining growth factor independence.
Awwad RA; Sergina N; Yang H; Ziober B; Willson JK; Zborowska E; Humphrey LE; Fan R; Ko TC; Brattain MG; Howell GM
Cancer Res; 2003 Aug; 63(15):4731-8. PubMed ID: 12907656
[TBL] [Abstract][Full Text] [Related]
33. Transgenic mice provide genetic evidence that transforming growth factor alpha promotes skin tumorigenesis via H-ras-dependent and H-ras-independent pathways.
Jhappan C; Takayama H; Dickson RB; Merlino G
Cell Growth Differ; 1994 Apr; 5(4):385-94. PubMed ID: 8043512
[TBL] [Abstract][Full Text] [Related]
34. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins.
Chiron MF; Fryling CM; FitzGerald D
J Biol Chem; 1997 Dec; 272(50):31707-11. PubMed ID: 9395513
[TBL] [Abstract][Full Text] [Related]
35. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
Theuer CP; FitzGerald DJ; Pastan I
J Urol; 1993 Jun; 149(6):1626-32. PubMed ID: 8501821
[TBL] [Abstract][Full Text] [Related]
36. Pseudomonas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-receptor interaction.
Shiah HS; Chen TY; Chang CM; Chow JT; Kung HJ; Hwang J
J Biol Chem; 1992 Nov; 267(33):24034-40. PubMed ID: 1429738
[TBL] [Abstract][Full Text] [Related]
37. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.
Seetharam S; Chaudhary VK; FitzGerald D; Pastan I
J Biol Chem; 1991 Sep; 266(26):17376-81. PubMed ID: 1910044
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic effects of vascular smooth muscle cells of the chimeric toxin, heparin binding TGF alpha-Pseudomonas exotoxin.
Fu YM; Mesri EA; Yu ZX; Kreitman RJ; Pastan I; Epstein SE
Cardiovasc Res; 1993 Sep; 27(9):1691-7. PubMed ID: 8287449
[TBL] [Abstract][Full Text] [Related]
39. An EGF-pseudomonas exotoxin A recombinant protein with a deletion in toxin binding domain specifically kills EGF receptor bearing cells.
Lee CH; Lee EC; Tsai ST; Kung HJ; Liu YC; Hwang J
Protein Eng; 1993 Jun; 6(4):433-40. PubMed ID: 8332601
[TBL] [Abstract][Full Text] [Related]
40. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
